🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interested in opportunities for #rarecancer patients from digitalisation? Join the RCE-ESMO-ESO Training for #PatientAdvocates session (10 Feb) ‘#Cancercare: ensuring digitalisation benefits rare #cancer patients’. Registration 👉 ow.ly/ZNt450HGejM ESOncology ESMO - Eur. Oncology

Today's session will be exploring the #EUCancerPlan & #EUCancerMission, as well as the Romanian national plan for #cancer, collaboration w/ the #rarecancer national network in Italy, pts involvement in HTA in Sweden & more… Register ➡️ ow.ly/8BW050HP5ru ESOncology ESMO - Eur. Oncology

From today's session, Ariane Weinman on rare cancers in the #EUCancerPlan, & new section on #rarecancers in the @EP_BeatCancer report. Bettina Ryll on how rare cancer pts will benefit from Horizon Europe Mission on Cancer, & vital role of #cancerresearch ow.ly/8BW050HP5ru

Great seeing all participants at today's session with some excellent discussions on topics around the European #rarecancer policy landscape, & looking foward to tomorrow's session on #rarecancers in the new #COVID-19 era. 👉ow.ly/ZNt450HGejM ESOncology ESMO - Eur. Oncology Paolo G Casali

From today's session on #rarecancers in the #covid19 era, Kathy Oliver discusses IBTA patient survey on #covid19vaccination & highlights that the continuity and quality of care for #rarecancerpatients should be protected ow.ly/ZNt450HGejM

Next up from today's session, Radu Ianovici presents main recommendations from @cancereu letter on #COVID19 & #cancer. The letter calls on policymakers to ensure pts get diagnosis & tx in a safe manner, & is signed by 320 organisations. 👉ow.ly/ZNt450HGejM #covid19ncancer

In the last part of today's session, Sergio Sandrucci, Sandrine Marreaud & Federica Castiglione shared their perspectives on the implications of #COVID19 on clinical research & healthcare professionals, & how #rarecancer pts communities can be supported 👉ow.ly/ZNt450HGejM

At today's session, Giancarlo Pruneri from Università degli Studi di Milano on #telepathology and #telemedicine, and how networking is a solution for #raretumours and #biomarkers 👉ow.ly/ZNt450HGejM #rarecancer ESOncology ESMO - Eur. Oncology

Second part of today's RCE-ESMO - Eur. Oncology-ESOncology Training for #PatientAdvocates brought together physicians, nurses and patients exploring the opportunities and challenges of #telepathology and #telemedicine for #rarecancer patients. ow.ly/ZNt450HGejM

#RareCancers in all policies: We are in this together, help us shape & develop an infrastructure to support #rarecancer patients across Europe, so they can have the best QoL possible ➡️ow.ly/ia9i50I0R5z CCI Europe 🎗️ @EP_BeatCancer EU One Health SIOPE 🎗️ EURORDIS-Rare Diseases Europe @cancereu

#RareCancers in all policies: "I know how devastating a rare cancer diagnosis can be as my son, Colin, was diagnosed w/ a #braintumour when he was 24. As a family we felt so isolated, alone & frightened." Kathy Oliver ow.ly/SL3B50I0SJJ #RareDiseaseDay IBTA

Risk reduction & screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Developed by multidisciplinary team incl. patient reps, w/ framework 4 managing clinical setting restricted by limited quality data. ow.ly/sBbi50Lk3z1 #HBOC

New 📢 #Salivaryglandcancer: ESMO Clinical Practice Guideline for diagnosis, tx & follow-up. Clinical & pathological diagnosis, staging & risk assessmt, & managemt. Tx algorithms given. ow.ly/Hr0050LsUPO Carla Van Herpen Rare Cancers Europe EURACAN #rarecancer ESMO Open

The safety results of durvalumab/tremelimumab/enfortumab vedotin #EMUC22 Alexandra Drakaki. Neoadjuvant triples for the VOLGA randomised trial! Ambitious!! The combo appeared safe with no clear ⬆️ skin, liver or neuro tox. pCRs in 6 downstaging in 9. The R3 is enrolling globally

In Annals of Oncology, investigators report on a clinico-genomic analyses of 1817 KRAS-mutated lung 🫁 adenocarcinomas, shedding light on genomic alterations 🧬 associated with outcome, towards a clinico-genomic risk stratification annalsofoncology.org/article/S0923-… #LCSM Dana-Farber

Perception of cancer by pts is based on organ-of-origin without mechanistic consideration. Franzoi Maria Alice et al explain why cancer representations should evolve toward comprehensive portraits that include biology. This is a task of the IHU Prism Center annalsofoncology.org/article/S0923-…

Osteosarcoma remains a disease with an unmet therapeutic need and imperfect risk stratification biomarkers. In Annals of Oncology, samuel abbou and coll. report on ctDNA quantification using lpWGS as a prognostic biomarker in the OS2006 phase 3 trial annalsofoncology.org/article/S0923-…